INTRODUCTION {#s1}
============

Cancer is caused by the dysfunction of intricate signaling pathways, leading to abnormal growth, metastasis, and many other events \[[@R1]\]. The transforming growth factor β (TGF-β) signaling pathway is one of major tumor-regulatory pathways, exerting critical tumor-suppressive functions in the early stages of tumorigenesis \[[@R2], [@R3]\]. When TGF-β signaling is activated, downstream SMAD2 and SMAD3 proteins are phosphorylated, forming a complex with SMAD4 and then translocating to the nucleus to turn on and off the transcription of a wide range of target genes \[[@R4], [@R5]\]. *SMAD7* inhibits TGF-β signaling by preventing the formation of the SMAD2/SMAD4 complex \[[@R6]\]. It also interacts with activated TGF-β type I receptor and blocks the phosphorylation and activation of SMAD2 \[[@R6]\].

*SMAD7* has also been reported to affect tumorigenesis via several other mechanisms. First, in FET-1 colon cancer cells, *SMAD7* induces the expression of I*κ*B, thereby repressing NF-*κ*B activity \[[@R7]\]. Secondly, *SMAD7* up-regulates MYC expression and WNT signaling via interactions with β-catenin in breast cancer \[[@R8]\] and hepatocellular carcinoma \[[@R9]\]. In addition, *SMAD7* inhibits ERK1/2, JNK1/2, and p38 MAPKs under some circumstances related with tumorigenesis, such as erythroid differentiation \[[@R10]\] and chondrocyte differentiation \[[@R11]\].

In 2007, Broderick and co-workers \[[@R12]\] conducted a genome-wide association study and identified three polymorphic variants in intron 3 of *SMAD7* (rs4464148, rs4939827, and rs12953717). Furthermore, they found these *SMAD7* polymorphisms were associated with CRC adenomas and carcinomas \[[@R12]\]. In a number of other studies these *SMAD7* polymorphisms have been associated with the risk of developing multiple cancers, including CRC \[[@R12]--[@R14]\], renal \[[@R15]\], and liver cancer \[[@R16]\]. However, other case-control studies have reported that these polymorphisms are not associated with cancer risk, in CRC \[[@R17]--[@R19]\], breast cancer \[[@R20]\], and lymphocytic leukemia \[[@R21]\]. These inconsistencies may be partially due to the relatively small sample sizes in each of these studies. Therefore, we performed a large-scale meta-analysis of all eligible published studies to derive a more precise quantitative assessment of the association between *SMAD7* polymorphisms and CRC risk.

RESULTS {#s2}
=======

Study selection and characteristics {#s2_1}
-----------------------------------

Figure [1](#F1){ref-type="fig"} is a flowchart explaining the study selection process. A total of 62 articles were initially retrieved from PubMed, Web of Science, EBSCO, and Embase electronic databases (last updated in June, 2016). Based on the search criteria, we excluded 33 ineligible records after carefully reviewing the full text and data, leaving 29 articles published between 2007 and 2016 for our quantitative meta-analysis.

![Flowchart of the literature selection process](oncotarget-07-75561-g001){#F1}

The characteristics of *SMAD7* polymorphisms (rs4464148, rs4939827, and rs12953717) in selected studies are shown in Table [1](#T1){ref-type="table"}. There were 64 eligible studies from 29 articles analyzing the relationship of *SMAD7* polymorphisms and CRC risk. Among these studies, one was conducted on rs12953717, with a relatively small sample size (308 subjects) \[[@R22]\], which seems to have affected the results dramatically. Therefore, this study was excluded from analysis. Finally, 63 studies (published from 2007-2016) including 187,181 subjects (86,585 cases and 100,596 controls) were used to estimate the risk of developing CRC with *SMAD7* polymorphisms. Each subpopulation in the literature was treated as a separate study in our meta-analysis. Populations were divided into ethnic categories. The Newcastle-Ottawa Scale (NOS) was used for quality assessment \[[@R23]\] and all of the studies achieved moderately high quality scores above 6 (Table [1](#T1){ref-type="table"}). Among the included studies, 12 were conducted on rs4464148 (18,303 cases and 16,964 controls), 37 on rs4939827 (48,751 cases and 61,529 controls), and 14 on rs12953717 (19,531 cases and 22,103 controls).

###### Main characteristics of all case-control studies included in the meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP              Author                                Year   Ethnicity   Cancer type   Case     Control   HWE (Control *P* value)   Study design   Genotyping method   Quality assessment                                       
  ---------------- ------------------------------------- ------ ----------- ------------- -------- --------- ------------------------- -------------- ------------------- -------------------- ------- ------------- ------------- ---
  **rs4464148**                                                                           **TT**   **TC**    **CC**                    **TT**         **TC**              **CC**                                                   

                   Broderick et al. \[[@R12]\]\          2007   Caucasian   Colon         389      425       116                       486            394                 80                   0.991   GWAS          Illumina      8
                   -A group                                                                                                                                                                                                        

                   -B group                              2007   Caucasian   Colon         2017     1952      472                       1886           1617                346                  0.982   Replication   Allele-PCR    8

                   -C group                              2007   Caucasian   Colon         922      845       193                       827            696                 146                  0.980   Replication   Allele-PCR    8

                   -D group                              2007   Caucasian   Colon         422      408       99                        171            137                 27                   0.952   Replication   Allele-PCR    8

                   Thompson et al. \[[@R28]\]            2009   Caucasian   Colon         269      231       61                        342            324                 53                   0.045   Replication   TaqMan        8

                   Curtin et al. \[[@R43]\]              2009   Caucasian   Colon         503      472       95                        535            423                 89                   0.678   Replication   SNPlex        8

                   Pittman et al. \[[@R44]\]             2009   Caucasian   Colon         1161     1107      264                       1095           1277                235                  0.996   Replication   Allele-PCR    8

                   Ho et al. \[[@R35]\]                  2011   Asian       Colon         739      146       7                         770            116                 4                    0.869   Replication   Sequenom      7

                   Zhang et al. \[[@R38]\]               2014   Asian       Colon         1        52        675                       14             305                 2957                 0.999   Replication   TaqMan        8

                   Kurlapska et al. \[[@R17]\]           2014   Caucasian   Colon         1214     1228      400                       84             96                  33                   0.523   Replication   Sequenom      7

                   Damavand et al. \[[@R29]\]            2015   Caucasian   Colon         138      78        37                        113            101                 20                   0.700   Replication   Taqman        7

                   Serrano-Fernandez et al. \[[@R45]\]   2015   Caucasian   Colon         507      517       141                       561            490                 114                  0.643   Replication   Taqman        8

  **rs4939827**                                                                           **CC**   **TC**    **TT**                    **CC**         **TC**              **TT**                                                   

                   Broderick et al. \[[@R12]\]\          2007   Caucasian   Colon         153      449       328                       229            480                 251                  0.987   GWAS          Illumina      8
                   -A group                                                                                                                                                                                                        

                   -B group                              2007   Caucasian   Colon         852      2178      1392                      845            1915                1084                 0.989   Replication   Allele-PCR    8

                   -C group                              2007   Caucasian   Colon         387      982       623                       410            840                 430                  0.995   Replication   Allele-PCR    8

                   -D group                              2007   Caucasian   Colon         194      477       292                       76             171                 96                   0.923   Replication   Allele-PCR    8

                   Tenesa et al. \[[@R14]\]\             2008   Caucasian   Colon         538      1521      926                       706            1508                845                  0.506   GWAS          Illumina      8
                   -Scotland(GWAS)                                                                                                                                                                                                 

                   -Japan                                2008   Asian       Colon         233      1582      2576                      131            1028                2019                 0.992   Replication   TaqMan        8

                   -Canada                               2008   Caucasian   Colon         225      593       355                       284            576                 322                  0.402   Replication   TaqMan        8

                   -England                              2008   Caucasian   Colon         418      1120      694                       546            1126                578                  0.959   Replication   TaqMan        8

                   -Spain                                2008   Caucasian   Colon         62       156       131                       57             143                 95                   0,808   Replication   TaqMan        8

                   -Germany                              2008   Caucasian   Colon         420      1071      659                       541            1057                530                  0.765   Replication   TaqMan-       8

                   -Germany                              2008   Caucasian   Colon         289      617       412                       378            704                 358                  0.403   Replication   TaqMan        8

                   -Scotland                             2008   Caucasian   Colon         156      420       254                       189            446                 288                  0.497   Replication   TaqMan        8

                   -Israel                               2008   Caucasian   Colon         267      638       447                       312            627                 397                  0.035   Replication   TaqMan        8

                   Curtin et al. \[[@R43]\]              2009   Caucasian   Colon         221      520       324                       229            538                 274                  0.251   Replication   SNPlex        8

                   Thompson et al. \[[@R28]\]            2009   Caucasian   Colon         125      275       154                       146            378                 185                  0.064   Replication   TaqMan        8

                   Pittman et al. \[[@R44]\]             2009   Caucasian   Colon         785      1250      497                       725            1300                582                  0.987   Replication   Allele-PCR    8

                   Slattery et al. \[[@R46]\]            2010   Caucasian   Colon         360      773       457                       492            992                 503                  0.947   Replication   TaqMan        8

                   Xiong et al. \[[@R33]\]               2010   Asian       Colon         1370     677       77                        1442           570                 74                   0.061   Replication   T-ARMS-PCR    8

                   von Hoslt et al. \[[@R47]\]           2010   Caucasian   Colon         395      886       501                       387            884                 408                  0.930   Replication   deCode test   8

                   Kupfer et al. \[[@R48]\]              2010   African     Colon         379      340       76                        455            429                 101                  0.994   Replication   Sequenom      7

                                                                Caucasian   Colon         88       199       112                       85             183                 99                   0.981   Replication   Sequenom      7

                   Mates et al. \[[@R49]\]               2010   Caucasian   Colon         28       37        27                        15             57                  23                   0.061   Replication   Centaurus     6

                   Mates et al. \[[@R50]\]               2011   Caucasian   Colon         42       69        42                        32             106                 43                   0.225   Replication   Centaurus     7

                   Cui et al. \[[@R34]\]                 2011   Asian       Colon         1628     1007      155                       2247           1190                147                  0.501   Replication   Illumina      8

                   Li et al. \[[@R22]\]                  2011   Asian       Colon         73       53        12                        81             73                  14                   0.665   Replication   Sequenom      7

                   Ho et al. \[[@R35]\]                  2011   Asian       Colon         343      420       129                       376            405                 109                  0.997   Replication   Sequenom      7

                   Song et al. \[[@R36]\]                2012   Asian       Colon         399      232       10                        732            272                 33                   0.214   Replication   TaqMan        6

                   Lubbe et al. \[[@R51]\]               2012   Caucasian   Colon         444      969       624                       1394           3021                1636                 0.993   Replication   Allele-PCR    7

                   Garcia-Albeniz et al. \[[@R52]\]      2012   Caucasian   Colon         90       233       118                       538            1120                600                  0.731   Replication   TaqMan        8

                   Phipps et al. \[[@R53]\]              2012   Caucasian   Colon         657      1526      884                       574            1597                1112                 0.988   Replication   TaqMan        7

                   Kirac et al. \[[@R54]\]               2013   Caucasian   Colon         63       143       96                        172            291                 131                  0.705   Replication   Illumina      8

                   Yang et al. \[[@R37]\]                2014   Asian       Colon         342      298       65                        891            752                 159                  0.985   Replication   Allele-PCR    7

                   Kurlapska et al. \[[@R17]\]           2014   Caucasian   Colon         54       93        65                        716            1394                730                  0.330   Replication   Sequenom      7

                   Zhang et al. \[[@R38]\]               2014   Asian       Colon         400      277       51                        1894           1170                212                  0.858   Replication   TaqMan        7

                   Hong et al. \[[@R19]\]                2015   Asian       Colon         126      63        9                         182            127                 19                   0.608   Replication   Illumina      7

                   Baert-Desurmont et al. \[[@R55]\]     2016   Caucasian   Colon         89       157       104                       191            493                 343                  0.555   Replication   SNaPshot      8

                   Abd EI-Fattah et al. \[[@R18]\]       2016   Caucasian   Colon         20       35        22                        11             15                  10                   0.319   Replication   TaqMan        7

  **rs12953717**                                                                          **CC**   **TC**    **TT**                    **CC**         **TC**              **TT**                                                   

                   Broderick et al.-A group \[[@R12]\]   2007   Caucasian   Colon         159      309       151                       326            467                 167                  0.991   GWAS          Illumina      8

                   -B group                              2007   Caucasian   Colon         1247     2204      973                       1248           1898                722                  0.994   Replication   Allele-PCR    8

                   -C group                              2007   Caucasian   Colon         582      991       422                       558            834                 312                  0.990   Replication   Allele-PCR    8

                   -D group                              2007   Caucasian   Colon         277      468       198                       106            168                 67                   0.976   Replication   Allele-PCR    8

                   Middeldorp et al. \[[@R13]\]          2009   Caucasian   Colon         301      493       201                       482            643                 215                  0.982   Replication   TaqMan        7

                   Curtin et al. \[[@R43]\]              2009   Caucasian   Colon         314      530       226                       332            521                 188                  0.509   Replication   SNPlex        8

                   Thompson et al. \[[@R28]\]            2009   Mixed       Colon         196      248       116                       220            370                 129                  0.218   Replication   TaqMan        8

                   Pittman et al. \[[@R56]\]             2009   Caucasian   Colon         716      1261      555                       859            1275                473                  0.998   Replication   Allele-PCR    8

                   Kupfer et al. \[[@R48]\]              2010   African     Colon         401      327       67                        525            388                 72                   0.979   Replication   Sequenom      7

                                                         2010   Caucasian   Colon         197      121       81                        119            180                 68                   0.996   Replication   Sequenom      7

                   Slattery et al. \[[@R46]\]            2010   Caucasian   Colon         503      754       332                       676            928                 327                  0.779   Replication   Illumina      8

                   Ho et al. \[[@R35]\]                  2011   Asian       Colon         276      343       97                        304            345                 65                   0.557   Replication   Sequenom      7

                   Scollen et al. \[[@R56]\]             2011   Mixed       Colon         710      1031      425                       730            1083                437                  0.326   Replication   TaqMan        8

                   Zhang et al. \[[@R38]\]               2014   Asian       Colon         418      263       47                        1947           1135                194                  0.096   Replication   TaqMan        8
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**SNP**: single nucleotide polymorphisms: **HWE**: Hardy-Weinberg equilibrium.

Quantitative data synthesis {#s2_2}
---------------------------

### *SMAD7* rs4464148 polymorphism {#s2_2_1}

For each study, we investigated the association between the *SMAD7* rs4464148 polymorphism and CRC risk, assuming different inheritance models. When all eligible studies were pooled into the meta-analysis, significant associations were found for the recessive genetic model (Table [2](#T2){ref-type="table"}): CC vs. TC+TT (OR = 1.23; 95% CI: 1.14--1.33; *P~Z~* \< 0.01; *P~H~* = 0.43\], while only a slight association was found for the dominant genetic model: CC +TC vs. TT (OR = 1.10; 95% CI: 0.99--1.22; *P~Z~* = 0.51; *P~H~* = 0.00). Subgroup analysis according to ethnicity showed that rs4464148 was significantly associated with CRC risk in both Caucasian and Asian populations (Table [2](#T2){ref-type="table"}).

###### Meta-analysis of the association between *SMAD7* polymorphisms and colorectal cancer risk

  SNP          Comparison       Subgroup    Heterogeneity test   Model   *P~Z~*   *P~E~*   OR (95% CI)   
  ------------ ---------------- ----------- -------------------- ------- -------- -------- ------------- ------------------
  rs4464148    CC *vs*. TT+TC   Overall     1.3                  0.43    F        \<0.01   0.13          1.23(1.14--1.33)
                                Caucasian   12.3                 0.33    F        \<0.01                 1.22(1.13--1.32)
                                Asian       0                    0.71    F        0.03                   1.39(1.04--1.87)
               CC+TC *vs.* TT   Overall     73.8                 0.00    R        0.07     0.51          1.10(0.99--1.22)
                                Caucasian   76.8                 0.00    R        0.16                   1.08(0.97--1.21)
                                Asian       0                    0.41    F        0.02                   1.36(1.05--1.75)
               C *vs*. T        Overall     66.2                 0.00    R        \<0.01   0.36          1.12(1.04--1.19)
                                Caucasian   67.7                 0.00    R        0.01                   1.10(1.02--1.18)
                                Asian       66                   0.09    F        \<0.01                 1.35(1.12--1.63)
  rs4939827    TT *vs*. CC+TC   Overall     73.3                 0.00    R        \<0.01   0.89          1.15(1.07--1.22)
                                Caucasian   61.2                 0.00    R        \<0.01                 1.19(1.12--1.26)
                                Asian       75.8                 0.00    R        0.73                   1.04(0.84--1.28)
               TT+TC *vs*. CC   Overall     71.8                 0.00    R        \<0.01   0.14          1.13(1.07--1.20)
                                Caucasian   71.6                 0.00    R        \<0.01                 1.16(1.08--1.24)
                                Asian       74.0                 0.00    R        0.31                   1.07(0.94--1.23)
               T *vs*. C        Overall     79.6                 0.00    R        \<0.01   0.45          1.11(1.06--1.16)
                                Caucasian   74.7                 0.00    R        \<0.01                 1.13(1.08--1.18)
                                Asian       56.9                 0.00    R        0.33                   1.07(0.94--1.21)
  rs12952717   TT *vs*. CC+TC   Overall     13.2                 0.31    F        \<0.01   0.54          1.22(1.16--1.29)
                                Caucasian   0                    0.87    F        \<0.01                 1.25(1.18--1.32)
                                Asian       54.9                 0.14    F        0.02                   1.31(1.04--1.65)
               TT+TC *vs*. CC   Overall     51.3                 0.02    R        \<0.01   0.66          1.15(1.08--1.23)
                                Caucasian   45.3                 0.06    F        \<0.01                 1.19(1.13--1.25)
                                Asian       0.0                  0.54    F        0.082                  1.12(0.99--1.28)
               T *vs*. C        Overall     51.5                 0.02    R        \<0.01   0.85          1.13(1.09--1.19)
                                Caucasian   29.8                 0.17    F        \<0.01                 1.16(1.12--1.20)
                                Asian       19.6                 0.27    F        0.02                   1.13(1.02--1.25)

*****P**~H~*** : *P* value of heterogeneity test; *****P**~Z~*** : *P* value of Z test; *****P**~E~*** : *P* value of Egger\'s test. R: random-effects model. F: fixed-effects model

### *SMAD7* rs4939827 polymorphism {#s2_2_2}

Similarly, we investigated the association between the *SMAD7* rs4939827 polymorphism and CRC risk. Significant associations were found for both the recessive (Figure [2](#F2){ref-type="fig"}): TT vs. TC+CC (OR = 1.15; 95% CI: 1.07--1.22; *P~Z~* \< 0.01; *P~H~* = 0.00) and the dominant genetic models: TT+ TC vs. CC (OR = 1.13; 95% CI: 1.07--1.20; *P~Z~* \< 0.01; *P~H~* = 0.00; Table [2](#T2){ref-type="table"}). Subgroup analysis according to ethnicity showed that rs4939837 was significantly associated with CRC risk in the Caucasian population (27 studies: 36,062 cases and 43,518 controls): TT vs. TC+CC (OR = 1.19; 95% CI: 1.12--1.26; *P~Z~* \< 0.01; *P~H~* = 0.00 for heterogeneity), whereas it had no association with CRC risk among Asians (9 studies: 12,607 cases and 16,349 controls): TT vs. TC+CC (OR = 1.04; 95% CI: 0.84--1.28; *P~Z~* = 0.73; *P~H~* = 0.00; Table [2](#T2){ref-type="table"}).

![Forest plot of cancer risk associated with the *SMAD7* polymorphisms in colorectal cancer studies with recessive genetic models\
The squares and horizontal lines correspond to the study-specific odds ratio (OR) and 95% confidence interval (95% CI). The area of the squares reflects the weight (inverse of the variance). **A.** *SMAD7* rs4464148; **B.** *SMAD7* rs4939827; **C.** *SMAD7* rs12953717.](oncotarget-07-75561-g002){#F2}

### *SMAD7* rs12953717 polymorphism {#s2_2_3}

In this meta-analysis, a strong association between the rs12953717 polymorphism and CRC risk was found for both the recessive: TT vs. CC+TC (OR = 1.22; 95% CI: 1.16--1.29; *P~Z~* \< 0.01; *P~H~* = 0.31) and the dominant genetic models: TT+TC vs. CC (OR = 1.15; 95% CI: 1.08--1.23; *P~Z~* \< 0.01; *P~H~* = 0.02; Table [2](#T2){ref-type="table"}). Further subgroup analysis based on ethnicity showed that rs12953717 was significantly associated with the risk of CRC in both Caucasians and Asians (Table [2](#T2){ref-type="table"}).

Sensitivity analyses and publication bias {#s2_3}
-----------------------------------------

Our results suggested that the influence of individual data sets to the pooled ORs were not significant. Sensitivity analysis showed that no single study qualitatively altered the pooled ORs, providing evidence of the stability of the meta-analysis ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). Funnel plots and Egger\'s test were performed to assess publication bias. The results suggested that there was no publication bias for the comparison of rs4464148 allele C vs. allele T (*t* =0.96, *P~E~* = 0.36), rs4939827 allele T vs. allele C (*t* =−0.76, *P~E~* = 0.45), or rs12953717 allele T vs. allele C (*t* =−0.19, *P~E~* = 0.85). The shape of Begg\'s funnel plot did not reveal any obvious asymmetry ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

TGF-β signaling is essential for maintaining homeostasis, cell differentiation, and tumor suppression \[[@R3], [@R24], [@R25]\]. Increased production of TGF-β occurs in various tumor types, such as CRC \[[@R26]\]. As one of the key effectors of TGF-β signaling, perturbation of *SMAD7* expression has been documented to influence CRC progression \[[@R7]\]\[[@R27]\]. Though the functional role of the *SMAD7* polymorphisms (rs4464148, rs4939827, and rs12953717) has not yet been interpreted, a number of published epidemiological studies have reported that these polymorphisms are correlated with the risk of developing multiple cancers \[[@R12], [@R28], [@R29]\]. However, other studies have reported that these polymorphisms are not associated with cancer development \[[@R17]--[@R20]\].

These conflicting studies based their conclusions on small numbers of samples and different detection methods. Therefore ameta-analysis from large-scale samples of all available studies is required to have a more accurate assessment as to whether the *SMAD7* polymorphisms are related to risk of developing CRC. Our group has already used meta-analysis to systematically investigate the association between cancer risk and several SNPs involved in TGF-β signaling \[[@R30]--[@R32]\]. In this meta-analysis, we found *SMAD7* polymorphisms (rs4464148, rs4939827, and rs12953717) in the combined population were all significantly associated with CRC risk. Subgroup analysis according to ethnicity showed that rs4464148 and rs12953717 were significantly associated with the risk of CRC among both Caucasian and Asian population, whereas rs4939827 seems to be a risk polymorphism for CRC only within a Caucasian population. There could be several possibilities to explain such a differential association. First, the difference in association may result from differences in socioeconomic environment, regional dietary habits, and race. Second, the number of rs4939827 in Asian studies is still not as large as desired. In addition, the results from nine studies incorporated in this meta-analysis conflict with each other \[[@R14], [@R19], [@R22], [@R33]--[@R38]\]. Therefore, more Asian studies are still needed to clearly evaluate the interactions of *SMAD7* rs4939827 and CRC in this ethnic group.

One recent study \[[@R39]\] also assessed the associations between these three SNPs and CRC risk by meta-analysis; however, there were significant limitations. First, the number of studies included in their analysis was smaller than ours. Only 4 publications for rs4464148, which also lack relevant studies for Asian population, and 13 publications for rs4939827 were included in their meta-analysis, while 9 publications for rs4464148 and 25 publications for rs4939827 were included in our work. Second, they only analyzed the relationship between *SMAD7* polymorphisms and CRC risk under an allelic model, while we also analyzed under dominant and recessive models. Therefore, our updated meta-analysis at a much larger scale clearly provides a more credible and reliable assessment for the association between *SMAD7* polymorphisms and the risk to develop CRC.

Nonetheless, we also wish to acknowledge the limitations in our study. First, we stratified the studies by ethnic subtypes as Caucasian and Asian. However, we could not assess the association in the African population due to the insufficient number of African studies. Second, further subtle adjusted analysis could be carried out if more detailed individual information was available. Third, we only assessed the association of *SMAD7* polymorphisms with CRC risk, because there were not sufficient studies conducted on other cancers.

To date, a large number of studies have focused on the relationship between *SMAD7* polymorphisms and cancer. However, controversies remain as whether those polymorphisms indeed associate with increased cancer risks. Our large-scale meta-analysis demonstrated that the C allele of rs4464148, the T allele of rs4939827, and the T allele of rs12953717 were all significantly associated with the increased CRC risk, which may provide a basis for genetic testing in the development of CRC. Consistent with our findings, Noci et al. \[[@R40]\] recently showed that *SMAD7* rs4939827 is also associated with cancer survival rate after therapy. Therefore, the identification of *SMAD7* polymorphisms may also benefit developing targeted and personalized therapy against CRC. However, more comparative studies are needed to evaluate interactions of *SMAD7* polymorphisms and cancer risk in other specific cancer subtypes and ethnic subtypes

MATERIALS AND METHODS {#s4}
=====================

Literature Search strategy {#s4_1}
--------------------------

We searched for relevant case-control studies using the following words and terms: "*SMAD7*", "Mothers against decapentaplegic homolog 7", "rs4464148", "rs4939827", "rs12953717", "polymorphism" or "variation", "susceptibility", and "tumor" or "cancer" or "carcinoma" or "neoplasia" or "colorectal caner" or "CRC" in PubMed, the Web of Science, EBSCO, and Embase databases. There were no limitations on the language and year for the literature search. The last search was updated on June 30, 2016. References of the retrieved publications were also screened.

Inclusion criteria {#s4_2}
------------------

Two authors independently screened titles and abstracts to identify relevant studies. Full-text articles of these studies were then carefully read to select eligible studies. Studies had to meet the following inclusion criteria: (a) were a case-control study, nested case-control or a cohort study; (b) evaluated the association between *SMAD7* polymorphisms ("rs4464148", "rs4939827", and "rs12953717") and CRC risk; (c) had available genotype frequencies both in cases and controls; (d) the genotype distribution in control groups was in Hardy-Weinberg equilibrium (HWE). (e) In cases of multiple studies with overlapping, redundant data published, only the most recent or complete study was included.

Qualitative assessment {#s4_3}
----------------------

Two authors independently conducted the quality assessment. The Newcastle--Ottawa Scale (NOS) was used to evaluate the study quality, which scored studies by the selection of the groups, the comparability of cases and controls, and the ascertainment of the exposure. We considered a study awarded 0-3, 4-6, or 7-9 as a low-, moderate-, or high-quality study, respectively \[[@R23]\].

Data extraction {#s4_4}
---------------

Two authors independently selected the relevant articles and extracted the following data: first author\'s name, publication date, ethnicity, cancer type, genotyping methods, number of cases and controls, and number of genotypes in case-control groups. In addition, *P* values according to the HWE in controls were extracted from the included studies.

Statistical analysis {#s4_5}
--------------------

Our meta-analysis was performed using Stata software (version 12.0; StataCorp LP, College Station, TX, USA). We first calculated the strength of the association between *SMAD7* polymorphisms and CRC by odds ratio (OR) corresponding to 95% confidence interval (CI) for different genetic models. Then we stratified the studies by ethnic subtypes and examined the association between *SMAD7* polymorphisms and the CRC risk (Table [2](#T2){ref-type="table"}). A chi-square-based *Q*-statistic test \[[@R41]\] was performed to evaluate the between-study heterogeneity of the studies. *P~H~* \< 0.05 was considered significant for heterogeneity. We also calculated the quantity *I^2^* that represents the percentage of total variation across studies. As a guide, values of *I^2^* less than 25% were considered "low", values about 50% were considered "moderate", and values greater than 75% were considered "high"\[[@R42]\]. The fixed effects model was used when there was no heterogeneity of the results of studies; otherwise, the random-effects model was chosen. A pooled OR obtained by meta-analysis was used to give a more reasonable evaluation of the association. The significance of the pooled OR was determined by *Z* test (*P~Z~* ≤0.05 suggests a significant OR). Funnel plots were used to access publication bias by the method of Begg\'s test and Egger\'s test. A *T* test was performed to determine the significance of the asymmetry. An asymmetric plot suggested possible publication bias (*P~E~* ≥ 0.05 suggests no bias).
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